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Gap junctions contain cell–cell communicating channels that consist of multimeric proteins called connexins and mediate the exchange of
low-molecular-weight metabolites and ions between contacting cells. Gap junctional communication has long been hypothesized to play a crucial
role in the maintenance of homeostasis, morphogenesis, cell differentiation, and growth control in multicellular organisms. The recent discovery
that human genetic disorders are associated with mutations in connexin genes and experimental data on connexin knockout mice have provided
direct evidence that gap junctional communication is essential for tissue functions and organ development. Thus far, 21 human genes and 20
mouse genes for connexins have been identified. Each connexin shows tissue- or cell-type-specific expression, and most organs and many cell
types express more than one connexin. Cell coupling via gap junctions is dependent on the specific pattern of connexin gene expression. This
pattern of gene expression is altered during development and in several pathological conditions resulting in changes of cell coupling. Connexin
expression can be regulated at many of the steps in the pathway from DNA to RNA to protein. However, transcriptional control is one of the most
important points. In this review, we summarize recent knowledge on transcriptional regulation of connexin genes by describing the structure of
connexin genes and transcriptional factors that regulate connexin expression.
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Gap junctions are specialized cell–cell junctions that directly
link the cytoplasm of neighboring cells. They mediate the direct
transfer of low-molecular-weight (<1000 Da) metabolites and
ions, including second messengers such as cyclic AMP, inositol
trisphosphate and Ca2+, between adjacent cells. Therefore, it has
long been hypothesized that gap junctional intercellular
communication plays a crucial role in the maintenance of
homeostasis, morphogenesis, cell differentiation, and growth
control in multicellular organisms. Recent discoveries of human
genetic disorders due to mutations in gap junction protein
(connexin [Cx]) genes and experimental data on connexin
knockout mice provide direct evidence that gap junctional
intercellular communication is essential for tissue functions and
organ development, and that its dysfunction causes diseases.
Thus far, 21 human genes and 20 mouse genes for connexins
have been identified [1]. Each connexin shows tissue- or cell-
type-specific expression, and most organs and many cell types
express more than one connexin (Table 1). Some connexins,
such as Cx32 and Cx43, are expressed in cells of many types, but
others are expressed in very limited organs and cells. Even in the
same tissue, the expression pattern of each connexin shows cell-
type specificity and developmental changes, suggesting the
presence of distinct but tight control mechanisms for regulation
of connexin gene expression. For example, in the adult mouse
heart tissue [2], Cx43 is expressed in all the cardiac components
excluding the sinoatrial (SA) and atrioventricular (AV) nodes,
the His bundle, and the proximal parts of the bundle branches
(BBs). On the other hand, Cx40 expression is restricted to the
atria, the AV node, and the His-Purkinje system. Similarly, Cx45
is restricted to the SA and AV nodes, around the His-Purkinje
system, and the most peripheral regions of the interventricular
septum. These cardiac connexins have different patterns of
expression during development; e.g., the pattern of Cx43expression is the inverse of the Cx40 expression pattern. Other
examples for cell-type-specific patterns of connexin expression,
connexin expression in the skin and central nervous system, are
shown in Table 2 [3,4] and Table 3. Transgenic approaches with
mice carrying an appropriate reporter gene (LacZ, placental
alkaline phosphatase, enhanced green fluorescent protein)
instead of the connexin coding region not only confirmed data
obtained from immunocytochemistry but also showed the
expression of connexins, which would otherwise have remained
undiscovered [5–8]. Studies using connexin-deficient mice also
have provided evidence as to which connexin is functional in a
certain cell type [5–9]. For recent reviews on gap junctions in
the nervous system, see references [10–12].
There is growing evidence that a single gap junction channel
can be made of different connexins, i.e., two connexons each
consisting of different types of connexins can form a
heterotypic gap junction channel, whereas one connexon
containing different types of connexins can form a heteromeric
gap junction channel. Distinct electrophysiological and ion-
selective properties have been shown not only for homotypic
gap junction channels made of different connexins but also
between homotypic and heterotypic gap junction channels. The
regulation of expression of each connexin can influence the
function of not only homotypic and heterotypic gap junctions
but also heteromeric gap junctions.
Cell coupling via gap junctions is dependent on the specific
pattern of connexin gene expression. This pattern of gene
expression is altered during development and in several
pathological conditions resulting in changes of cell coupling.
Like other genes, connexin expression can be regulated at
many of the steps in the pathway from DNA to RNA to protein,
i.e., transcriptional control, RNA processing control, RNA
transport and localization control, translational control, mRNA
degradation control, and protein activity control. Among these
six steps, however, transcriptional control is the most important
Table 1
Connexin genes and their expression
Human Mouse Major expressed organ or cell types
Name Chromosomal locus Name
Molecular mass
nomenclature
HUGO (Greek letter)
nomenclature
Molecular mass
nomenclature
hCx23 ? mCx23 –
hCx25 – 6 – –
hCx26a GJB2 13q11–q12 mCx26a Breast, cochlea, placenta, hepatocytes, skin,
pancreas, kidney, intestine
hCx30 GJB6 13q12 mCx30 Brain, cochlea, skin
hCx30.2 GJE1 7q22.1 mCx29 Brain, spinal cord, Schwann cells
hCx30.3 GJB4 1p35–p34 mCx30.3 Skin, kidney
hCx31 GJB3 1p34 mCx31 Cochlea, placenta, skin
hCx31.1 GJB5 1p35.1 mCx31.1 Skin
hCx31.9 GJC1 (GJA11) 17q21.1 mCx30.2 –
hCx32 GJB1 Xq13.1 mCx32 Hepatocytes, secretory acinar cells, Schwann cells
– – – mCx33 Sertoli cells
hCx36 GJA9 15q13.2 mCx36 Neurons, pancreatic h-cells
hCx37 GJA4 1p35.1 mCx37 Endothelium, granulosa cells, lung, skin
hCx40 GJA5 1q21.1 mCx40 Cardiac conduction system, endothelium, lung
hCx40.1 – – mCx39 –
hCx43 GJA1 6q21–q23.2 mCx43 Many cell types
hCx45 GJA7 17q21.31 mCx45 Cardiac conduction system, smooth muscle
cells, neurons
hCx46 GJA3 13q11–q12 mCx46 Lens
hCx47 GJA12 1q41–q42 mCx47 Brain, spinal cord
hCx50 GJA8 1q21.1 mCx50 Lens
hCx59 GJA10 1p34 – –
hCx62 – 6q15–q16 mCx57 Retinal horizontal cells
a Orthologous genes of human and mouse connexin genes are listed in the same line.
M. Oyamada et al. / Biochimica et Biophysica Acta 1719 (2005) 6–238[13–15]. In this review, we summarize recent knowledge on
transcriptional regulation of connexin genes by describing the
structure of connexin genes, and transcriptional factors and
biological substances that regulate connexin expression.
2. Gene structure of connexins
Early studies seemed to show that the general genomic
structure of connexin genes is rather simple, i.e., a 5V-
untranslated region (5V-UTR) on exon 1 is separated from the
complete connexin coding region and the subsequent 3V-
untranslated region (3V-UTR), both located on exon 2. However,Table 2
The expression of connexins in skin
Human Rodent
Epidermis
Basal cell layer Cx26; (Cx43) Cx43; Cx40; Cx37; (Cx31)
Spinous cell layer Cx43>Cx31>Cx37 Cx43; Cx37; Cx31.1;
Cx31; Cx30.3
Granular cell layer Cx43>Cx31>Cx37 Cx37; Cx31.1; Cx31;
Cx30.3; (Cx30; Cx26)
Hair follicle
Internal root sheath Cx26>Cx43 Cx31; Cx26
Outer root sheath Cx43>Cx26 Cx43>Cx40
Sebaceous glands Cx43 Cx31>Cx40/Cx43
Eccrine sweat glands Cx31; Cx26; (Cx43) Cx31; Cx26
Dermal fibroblasts Cx43; Cx40 Cx43
Human data from [3] and rodent data from [3] and [4]. Connexins in
parentheses were found in small amounts.recent data on genomic organization of several connexin genes
refutes this simplicity. First, many different splice isoforms of
several connexin genes have recently been identified, indicating
that different 5V-UTRs can be spliced in a consecutive and/or
alternate manner possibly due to alternate promoter usage.
However, it should be emphasized that these transcript isoforms
vary only in their untranslated, mostly 5V-UTRs that leave their
coding regions unaltered. Second, the coding region can be
interrupted by introns, e.g., Cx36, Cx39, and Cx57 genes [1].We
will discuss the gene structure of several connexin genes in some
detail in the following sections.
2.1. Cx32
Miller et al. [16] first reported the structure of the rat Cx32
gene and showed that the 5V-UTR of the transcript in the liverTable 3
The expression of connexins in the central nervous system
Expressed
connexins
Functional connexins demonstrated
by targeted ablation in mice
Neurons Cx36, Cx45, Cx57 Cx36 [9], Cx45 [8], Cx57 [6]
Astrocytes Cx30, Cx43, Cx26 Cx30, Cx43
Oligodendrocytes Cx29, Cx32, Cx47 Cx47 [5]
Leptomeningeal
cells
Cx26, Cx30, Cx43
Ependymal cells Cx30, Cx43
Microglia Cx36, Cx43
Data for expressed connexins are based on [10–12].
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coding exon (in this review, the nomenclature used for an
exon localized at most 5V regions is exon 1) upstream of the
intron, while the complete coding sequence is not interrupted
by an intron but contained within one exon (in this review, the
nomenclature used for this exon is exon 2). It is now known
that multiple alternatively spliced transcripts of Cx32 gene
exist in mammalian species, i.e., two different transcripts in
the rat [17,18] and human [19], and three different transcripts
in the cow [20] and mouse [21]. It can be generalized that in
the hepatocyte and secretory acinar cell, Cx32 mRNA is made
from the promoter 1 (P1) upstream of exon 1 and in Schwann
cells from an alternative promoter 2 (P2) upstream of exon 1B
that is located upstream of the coding exon (exon 2).
Therefore, promoter P2 is called nerve-specific promoter (in
this review, the nomenclature used for an exon downstream of
the nerve-specific promoter of Cx32 gene is exon 1B). In
cattle and mice, exon 1A is localized between exon 1 and
exon 1B (Fig. 1).
Human Cx32 gene consists of three exons (1, 1B, and 2)
that are alternatively spliced to produce mRNAs with different
5V-UTR [19]. Transcription is initiated from two tissue-specific
promoters. In liver and pancreas, promoter P1, located more
than 8 kb upstream of the translation start codon, is used, and
the transcript is processed to remove a large intron. In contrast,
in nerve cells, transcription is initiated from promoter P2,
located 497 bp upstream from the translation start codon, and
the transcript is processed to remove a small 355-pb intron. The
downstream exon 2, which includes the entire coding
sequence, is shared by both mRNAs.
Mouse Cx32 gene contains at least four exons, 1, 1A, 1B,
and 2 [21]. Exon 1 is mapped about 6.5 kb upstream of exon
2, which harbors the entire coding region. Exon 1A is
localized approximately 2 kb upstream of exon 2. Exon 1B is
located 310 bp upstream of exon 2. Three transcripts (E1/E2,
E1A/E2, E1B/E2) have been identified. Transcript E1/E2 is
transcribed in the hepatocyte using the promoter P1 upstream
of exon 1, whereas transcript E1B/E2 is transcribed in the
Schwann cell using promoter P2 upstream of exon 2.
Transcript E1A/E2 is transcribed in embryonic cells, oocytes,
and liver. Bovine Cx32 gene also has at least four exons
[20].Fig. 1. Structure and splice patterns of the human, rat, mouse, and bovine Cx32 genes
coding sequences. Bovine exon 1A is not identical with mouse exon 1A.Rat Cx32 gene contains at least three exons, 1, 1B, and 2
[17]. Two transcripts (E1/E2, E1B/E2) have been identified.
The upstream promoter P1 that directs the synthesis of
transcript E1/E2 is active in epithelial cells (liver, pancreas),
whereas the downstream promoter P2 that directs transcript
E1B/E2 is active in peripheral nerves.
The promoter P1 contains putative binding sites not only for
cell type-independent (ubiquitous) transcription factors, such as
binding sites for Sp1/Sp3 [22–24], nuclear factor 1 (NF-1)
[25], and Yin Yang 1 (YY1) [24], but also for cell-type-
dependent transcription factors including hepatocyte nuclear
factor-1 (HNF-1) [22,25,26]. The nerve-specific promoter P2
also includes binding sites for cell-type-specific transcription
factors such as Sox10 and early growth response gene-2 (Egr2/
Knox20) [27,28]. Each transcription factor will be described
below.
2.2. Cx40
Concerning Cx40 mRNA, two different transcripts are
found in the human [29], three different transcripts in the
mouse [30], and one transcript in the rat have been found. More
importantly, these different transcripts are transcribed in a
tissue-specific manner in the human and mouse (Fig. 2).
Human Cx40 gene contains at least three exons, 1A, 1B and
2, which are present in two lineage-specific variants: transcript
1A and transcript 1B are derived from alternative 5V non-coding
exons (exon 1A and 1B) [29]. Each of two exons is transcribed
independently [transcript 1A (E1A/E2) and transcript 1B (E1B/
E2)]. These transcripts are transcribed in a cell-type-specific
manner; e.g., human umbilical cord vein endothelial cells
(HUVEC) express only transcript 1A, while the human
choriocarcinoma cell lines BeWo, JAR, and JEG-3 and purified
cytotrophoblasts from first-trimester human placenta express
only transcript 1B. In the human heart, however, both
transcripts were found to be expressed in various regions,
i.e., left atrium, right atrium, left ventricle, and right ventricle.
Quantitative real-time RT-PCR analysis showed that transcript
1B is always less abundant than transcript A in these different
regions in the heart: for example, transcript 1B was 3- and 28-
fold less abundant than transcript 1A in the left atrium and left
ventricle. In the case of the human heart, it should be noted that. Exon (E) sequences are shown as boxes, whereas the solid grey parts represent
Fig. 2. Structure and splice patterns of the mouse, rat, and human Cx40 genes. Exon (E) sequences are shown as boxes, whereas the solid grey parts represent coding
sequences.
M. Oyamada et al. / Biochimica et Biophysica Acta 1719 (2005) 6–2310each cardiac tissue contains not only cardiomyocytes but also
vascular endothelial cells, both of which express Cx40.
Therefore, it remains to be elucidated which transcript is
expressed in the cardiomyocyte and whether different tran-
scripts are expressed in cardiomyocytes from the various
regions.
In the mouse Cx40 gene, three 5V-UTR exons, exon 1A, 1B,
and AS, and three transcripts (E1A/E2, E1B/E2, E1B/AS/E2)
were very recently identified [30]. A transcript containing exon
AS is nearly absent in mouse embryo and heart, but it is
especially abundant in the esophagus. On the other hand,
transcripts that include exon 1a were reported to be ubiquitous
in all the tissues tested.
In the rat, no alternative Cx40 transcripts have so far been
reported [31]. Human Cx40 exon 1A is orthologous to the
mouse Cx40 exon 1B and rat Cx40 exon 1.
2.3. Cx43
Cx43 gene was originally described as consisting of two
exons, one containing most of the 5V-UTR and the other
containing the protein sequence and 3V-UTR [32–35]. How-
ever, Pfeifer et al. [36] reported that in mice there are four
additional exons, all of which code for novel 5V-UTRs. They
showed that altogether six exons, five of which code for 5V-
UTRs (exon 1A–1E), one for the coding region (exon 2), and
three alternate promoter regions (P1–P3) are present in the
mouse Cx43 gene, and that four of the six exons (exon 1A–1C,
exon 2) found in the mouse are also present in the rat. No
equivalents of mouse exons 1D or 1E were found in the rat
(Fig. 3). In the human, however, no alternate 5V-UTR has been
found so far.
Pfeifer et al. [36] also showed that in the mouse, nine
different Cx43 mRNAs (transcripts E1As/E2, E1A/E2, E1AL/
E2, E1A/E1E/E2, E1Bs/E2, E1Bs/E1D/E2, E1BL/E2, E1C/E2,
E1C/E1D/E2) are generated by differential promoter usages
and alternative splicing mechanisms. In rats, six different Cx43
mRNA species (transcripts E1As/E2, E1A/E2, E1AL/E2, E1B/
E2, E1Cs/E2, E1CL/E2) were similarly found. In the mouse
Cx43 gene, in addition to the promoter P1, which was
previously known to be a Cx43 promoter, two additionalpromoters downstream of promoter P1 were found; promoter
P2 is located within exon 1A, and promoter P3 is located in the
intron just upstream of exon 1C. In the heart, promoter P1 is
active throughout the organ. Promoter P2 is active in the atrium
and septum but not in the ventricle. Promoter P3 is functional
only in ventricles and not in atria and septum. Alternative
splicing and exon choice seem to be cell-type specific, because
transcripts containing exon 1B preferentially skip exon 1D in
the septum, whereas in the atrium exon 1D is included in about
half of the transcripts.
Carystinos et al. [37] have proposed that the P2 promoter
mediates upregulation of Cx43 expression through the Ras
signaling pathway and the putative consensus sequence,
AGTTC(A/C)A(T/C)CA , was found in the human, mouse
and rat Cx43 gene. They showed that this element is
recognized by a protein complex that includes c-Myc and
HSP90.
Cx43 is the only connexin for which a pseudogene has been
reported so far. A pseudogene of Cx43 that lacks an intron of
the Cx43 gene has been identified on human chromosome 5,
whereas the Cx43 gene has been assigned to human
chromosome 6 [38]. Kandouz et al. [39] identified the presence
of a pseudogene Cx43 mRNA transcript in several cancer cell
lines and in none of the normal mammary epithelial cells
studied. They showed that Cx43 pseudogene can be translated
in an in vitro translation system, and that the Cx43 pseudogene
product inhibits cell growth without affecting gap-junctional
intercellular communication.
2.4. Cx45
The mouse Cx45 gene is composed of five exons (exons
1A, 1B, 1C, 2, and 3), two of which (exons 1A and 1B) were
only very recently reported [30]. Exons 1A, 1B, 1C, and 2
contain only 5V untranslated sequences, and exon 3 contains the
remaining 5V-UTR, entire coding sequence and 3V-UTR. Each
of exon 1A, 1B, and 1C is spliced to exon 2 and exon 3. A
transcript that directly starts at exon 2 is also present [30,40].
Thus, various transcripts (E1A/E2/E3, E1B/E2/E3, E1C/E2/E3,
E2/E3) are generated. Transcription of Cx45 from each
alternative promoter is tissue-specific, i.e., although transcripts
Fig. 3. Structure and splice patterns of the mouse Cx43 (A) and rat Cx43 (B) genes, and promoters of the mouse Cx43 gene (C). Exon (E) sequences are shown as
boxes, whereas the solid grey parts represent coding sequences. (A, B) Exon 1AS and exon 1A partially overlap. (C) The positions of the transcription start sites are
indicated by arrows. The locations of the P1, P2, and P3 promoters are shown by arrowheads. Reproduced from [36] with permission.
M. Oyamada et al. / Biochimica et Biophysica Acta 1719 (2005) 6–23 11containing exon 1A is nearly ubiquitous, exon 1B was found in
trace amounts in colon RNA and exon 1C was found colon,
bladder, lung, skeletal muscle, ovary, heart, and E14.5 embryo
total RNA. Multiple upstream ORF are found in exon 1A and
exon 1C [30,40] (Fig. 4A).
Teunissen et al. [15] performed comparative analysis of the
Cx45 gene between human and mice, and revealed conserva-
tion of E2 and E3 sequence between the two species.
Baldridge et al. [41] found a potential TATA box and two
putative AP-1 binding sites in the 5V region of the mouse Cx45
gene, but no functional analysis of the regulatory region of
Cx45 has yet been performed.
2.5. Cx31
Three exons (exons 1A, 1B, and 2) have so far been
identified in the mouse Cx31 gene. The two exons that
comprise the 5V-UTR, exons 1A and 1B, lie ¨3.7 kb and 2.3 kb
upstream of exon 2 (coding exon), respectively [30,42].
Anderson et al. [30] very recently described exon 1A, a novel
exon, which appears to be transcribed from previously
unknown promoters. They showed that transcripts that include
exon 1A are widely distributed in adult tissues, including the
skin, but are absent from the brain, and that multiple
transcription start sites are present in exon 1A (Fig. 4B).
Mouse exon 1B was cloned and described by Henneman et
al. [43]. A proximal promoter region extending to 561 bp
upstream of mouse exon 1B serves as a basal promoter in bothmouse embryonic stem (ES) cells and a mouse keratinocyte-
derived cell line. The rat exon 1 shows high homology (93%)
with mouse exon 1B [42]. Two transcription start sites are
identified in exon 1 in the rat. However, in the human Cx31
gene, only the second exon, which contains complete coding
region and a part of intron, has been characterized [44].
Both mouse Cx31 exon 1B and rat Cx31 exon 1 are
preceded by a TATA-less promoter region. No GC boxes
(which may control transcriptional initiation in TATA-less
promoters) via binding to the ubiquitous transcription factor
Sp1 were found in the (basal) promoter region [42,45]. In rat
Cx31 promoter region (935 bp upstream of the 5V flanking
region of exon 1), five putative GATA-2/ GATA-3 binding
sites, and putative binding sites for NFnB, CCAAT-box,
cEBPa/CEBh, c-AMP-responsive element, and multiple E-
box/E-box are found. Despite the presence of multiple binding
sites for GATA factors in the putative promoter region of rat
Cx31 gene, cotransfection experiments with GATA-3 expres-
sion had no influence on the promoter activity of Cx31. At
further upstream of basal promoter region (between 3000 and
2200 bp upstream), positive cell-specific regulatory element
is found in the rat Cx31 gene [42].
In the mouse, expression of Cx31 in keratinocytes and ES
cells is regulated by different cis-regulatory elements and
differs in its requirements for the intron in situ [45]. A region
between 561 and 841 bp upstream of mouse Cx31 exon 1B is
essential and sufficient for substantial transcription of Cx31 in
mouse keratinocyte-derived Hel37 cells, whereas an intron
Fig. 4. Structure and splice patterns of the mouse and human Cx45 genes (A), mouse and rat Cx31 genes (B), human Cx30 gene (C). Exon (E) sequences are shown
as boxes, whereas the solid grey parts represent coding sequences.
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ES cells but not in keratinocyte-derived cells. Splicing is
shown to be required for intron-dependent expression
enhancement of Cx31 in ES cells because mutations in the
splice donor site that prevent transcript processing cause
decreased expression of Cx31. The enhancing effect of the
intron of the rat Cx31 gene was also found in the mouse
keratinocyte line Hel37 as well as in the choriocarcinoma cell
line Rcho-1 [42].
2.6. Cx30
Essenfelder et al. [46] reported that six different exons are
present in the human Cx30 gene. They showed that exon 1 to
exon 5 are non-coding exons while exon 6 is a coding exon,
and that some of the Cx30 exons can be alternatively spliced,
so that the 5V non-coding region of Cx30 transcripts is highly
variable. They found that in hair follicle keratinocytes, at least
four different splicing variants are present and only exon 5 is
present in all transcripts, whereas exon 3, which has been
described in human brain cDNA, is absent from Cx30
transcripts from epidermis. Their data suggest that in
epidermis, Cx30 transcription starts at exon 1, whereas in
cells from the nervous system transcription would start from
exon 3 (Fig. 4C).
In the promoter region of the human Cx30 gene, upstream
of exon 1, a TATA motif (TTAAAA), several potential bindingsites for Sp1, and consensus sequence (CGCCCCCGC) for the
early growth response gene product (Egr)-binding are present
[46].
The usage of alternative promoters to produce different 5V-
UTR of connexin mRNAs has also been reported on mouse
Cx46 and Cx47 [30].
2.7. Cx26
In contrast to other connexin genes described above, thus
far, only two exons, i.e., non-coding exon 1 and exon 2
containing complete connexin coding region and the subse-
quent 3V-UTR, are known to be present in the mammalian Cx26
gene. In the mouse Cx26 gene, the length is 234 bp for exon 1
and 3.8 kb for intron 1 [25]. Similarly, in the human Cx26
gene, the length is 160 bp for exon 1 and 3148 bp for intron 1
[47]. In the promoter P1 upstream of exon 1, several GC boxes
for Sp1/Sp3 binding sites and a TTAAAA box are identified in
the mouse [25] and human [47,48] Cx26 genes.
2.8. Cx36, Cx39, and Cx57 genes, whose coding regions are
interrupted by introns
The coding regions of Cx36, Cx39, and Cx57 genes have
been shown to be located on two (or more) different exons. The
coding region is interrupted by a 1.14-kb intron, which
separates the first 71 bp, starting with ATG, from the rest of
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genes. The coding region of the mouse Cx39 is also interrupted
by a 1.5-kb intron, which separates exon 1, coding 21 amino
acids, and exon 2, coding 343 amino acids [51]. Concerning
mouse Cx57 gene, Hombach et al. [6] found that, at least in the
retina, these most C-terminal amino acid residues were
replaced after splicing with 12 different amino acid residues
coded further downstream. As a result, 97.6% (480 amino
acids) of the coding region of mouse Cx57 gene is located on
exon 2, whereas the residual 2.4% (12 amino acids) is encoded
on a third exon, which is separated by an intron of about 4 kb.
When connexin genes contain coding regions that are inter-
rupted by introns, these coding regions have to be spliced
properly in order to become translated. Otherwise, alternative
splicing (which has not, however, been demonstrated yet)
would lead to a dramatic modification of the connexin coding
region.
3. Transcriptional factors, biological substances, and signal
transduction pathways that regulate expression of connexin
genes
As described above, in most connexin genes, the basal
(canonical, proximal) promoter P1 is located within 300 bp
upstream of the transcription initiation site in exon 1. Within
the region, binding sites for cell type-independent (ubiquitous)
and -dependent transcription factors have been identified in
several connexin genes. For example, the former include
binding sites for TATA box-binding protein, Sp1/Sp3, and AP-
1. The latter include binding sites for cardiac-specific
transcription factors (Nkx2-5, GATA4, Tbx5), and HNF-1.
Although a sharp distinction between cell type-independent
(ubiquitous) and -dependent transcription factors is sometimes
difficult to make, we adopt this classification for the
convenience of description.
3.1. Cell type-independent (ubiquitous) transcription factors,
biological substances, and signal transduction pathways that
regulate connexin expression
3.1.1. Sp1
Sp1 is a ubiquitous transcription factor that has a DNA-
binding domain that consists of three zinc fingers and
recognizes the GC box. Sp-1 binding sites have been identified
in connexin genes, and they appear to be a common important
element in the basal transcriptional activity of several connexin
genes, such as Cx32 [22–24], Cx40 [29,52–55], Cx43 [56–
60], and Cx26 [48,61]. For example, Teunissen et al. [54,57]
characterized the proximal promoters P1 of rat Cx40 (175,
+85) and Cx43 (148, +281) genes, in which, respectively,
five and four potential binding sites for Sp-family transcription
factors were found. They showed that each of these sites
contributes to promoter activities and binds both the transcrip-
tion factors Sp1 and Sp3. They also demonstrated that both Sp1
and Sp3 activated the rat Cx40 and Cx43 promoters P1, and
that random disruption of two of the Sp1/Sp3 binding sites
almost completely abolished promoter activity of Cx40 genes.Concerning Cx32, Bai et al. [23] identified two Sp1 binding
sites in a basal promoter P1 localized between 179 bp and
134 bp in the rat Cx32 gene. Piechocki et al. [22] also
showed that specific nuclear protein–DNA complexes that
bound to Sp1 consensus sites within the rat Cx32 basal
promoter element (nt 134 to 33) were formed using nuclear
extracts from both MH1C1 rat hepatoma cells that express
endogenous Cx32 and WB-F344 rat liver epithelial cells that
do not. The basal promoter element of rat Cx32 gene (nt 134
to 33) was 1.4-fold more active in MH1C1 cells than in WB-
F344 cells, whereas the entire promoter fragment (nt 754 to
33) was 4-fold more active in MH1C1 cells. These data
indicate that Sp1 is necessary for Cx32 promoter P1 basal
activity, but that some other transcription factor(s) determines
the cell-specific expression of Cx32.
3.1.2. Activator protein 1 (AP-1)
Activator protein 1 (AP-1) is composed of homo- or
heterodimers of the Jun, Fos, activating transcription factor
(ATF), and musculoaponeurotic fibrosarcoma (MAF) proteins
via leucine zipper structure and regulates various responses of
cells to stimuli. AP-1 binds to a consensus sequence [TGAC
(T/G) TCA] in the promoter and induces transcription of the
gene. One or more AP-1-binding sites have been identified in
the mouse, rat, and human Cx43 proximal promoters P1
(approximately 150 nucleotides up- and downstream of the
transcription initiation site) (the rat Cx43 promoter contains
two AP-1-binding sites [57], whereas the mouse and human
promoters each have one AP-1-binding site). The importance
of AP-1 transcription factors in regulation of Cx43 expression
in the onset of labor by allowing for an increase in myometrial
muscle cell coupling has been demonstrated [35,59,62].
Mitchell and Lye [63] very recently reported that dimers
comprising Fos/Jun proteins conferred greater transcriptional
activity than Jun dimers, with the Fra-2/JunB combination
conferring the greatest activity, and that expression of Fra-2
increases earlier than other Fos family members and confers the
highest transcriptional drive to the Cx43 promoter, suggesting
that Fra-2 is a central component in the regulation of Cx43
expression during labor.
3.1.3. Cyclic AMP
It has long been known that cyclic AMP (cAMP) enhances
gap junction formation and gap-junctional intercellular com-
munication in many cell types. Concerning gap junctions
made by Cx43, it is now understood that such enhancement
by cAMP is achieved via at least two different mechanisms:
initial rapid redistribution of Cx43 to the cell membrane, and
later stimulation of Cx43 gene expression. Putative cAMP-
responsive element had been identified in the rat Cx43
proximal promoter over a decade ago [34]. Civitelli et al. [64]
demonstrated that when rat Cx43 promoter P1 [including
1,339 bases 5V from the transcriptional start site (+1) and 222
bases 3V]-luciferase transfected rat osteogenic sarcoma cells
(UMR 106-01 cells) were treated with 8Br-cAMP for 6 h, the
amount of luciferase activity increased to 2 times the basal
activity. van der Heyden et al. [65] also showed that
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promoter P1 (containing exon I and 1250 bp of upstream
sequence)-luciferase, and that enhancement of Cx43 promoter
activity by cAMP is additional to that by the Wnt pathway,
which will be discussed below, indicating that cAMP and
Wnt signaling pathways act in parallel on the Cx43 promoter
P1. However, to our knowledge, there are no reports showing
that the putative cAMP-responsive element in the proximal
Cx43 promoter is really needed for enhancement of Cx43
expression by cAMP or that protein complexes bind to the
element.
3.1.4. Retinoids
Like cAMP, retinoids have long been known to induce
gap-junctional intercellular communication and upregulate
Cx43 expression in normal and preneoplastic cells. Rogers
et al. [66] showed that after treatment of confluent 10T1/2
cells with the synthetic retinoid tetrahydrotetramethylnaptha-
lenylpropenyl-benzoic acid (TTNPB) (108 M) caused an
approximate 10-fold elevation of Cx43 gene transcripts after
72 h. However, the molecular mechanism for upregulated
expression of Cx43 remained to be understood. Clairmont et
al. [67,68] hypothesized that retinoic acid increased Cx43
expression in F9 teratocarcinoma cells by stabilizing Cx43
transcripts. On the other hand, Vine et al. [56] reported that
neither did retinoids require protein synthesis for induction of
Cx43 mRNA nor was the 5.0 h half-life of Cx43 mRNA
altered. They showed, using two Cx43 promoter-luciferase
constructs (pCx2400luc, which contains the region of the
human Cx43 promoter between 2200 bp and +209 bp of the
transcriptional start site, and pCx350luc, a smaller fragment
of the human Cx43 promoter P1 containing a region between
158 and +209 bp of the transcription start site), that TTNPB
treatment resulted in upregulated activity of both of the Cx43
promoter constructs. They found the responsive region within
158 bp and +209 bp of the transcription start site; this
contains a Sp1/Sp3 GC-box to which Sp1 and Sp3 are bound,
as revealed by electrophoretic mobility shift assays (EMSA),
but no retinoic acid response element (RARE), and showed
that site directed mutagenesis of a GC-box in this region
increased basal levels of transcription and loss of retinoid
responsiveness. These results indicate that retinoids transcrip-
tionally activate Cx43 expression.
3.1.5. Wnt pathway
Wnt genes encode a large family of secreted glycoproteins
which play important roles in directing cell fate and cell
behavior, not only during embryonic development and in adult
life, but also in tumorigenesis [69]. Wnt proteins are thought to
act via the Frizzled class of cell-surface proteins. Receptor
activation leads to inhibition of glycogen synthase kinase 3h
(GSK3h), resulting in stabilization and accumulation of
nonphosphorylated h-catenin within the cytosolic compart-
ment. Increased abundance of this pool is associated with entry
of h-catenin into the nucleus, where members of the T cell
factor/lymphocyte enhancer binding factor (TCF/LEF) family
of transcription factors physically interact with h-catenin. Inthe nucleus, before Wnt signaling, TCF/LEF members bind to
DNA with sequence specificity in promoter and enhancer
regions of target genes, and along with Groucho and C-
terminal binding protein (CtBP), often repress gene expression.
Nuclearly localized h-catenin/TCF complexes are supposed to
activate transcription of target genes by binding to the specific
consensus sequence A/TA/TCAAAG, known as the TCF/LEF
binding site.
van der Heyden et al. [65] performed a computer search for
TCF/LEF regulatory elements in the rat Cx43 promoter P1 and
found that this promoter contains two TCF/LEF binding
consensus sequences in opposite orientations, i.e., TCF/LEF
site 1 is located at 1394 bp while site 2 is located at 714 bp
with respect to the transcription start site, and a third consensus
sequence is found in the first intron following a non-translated
short exon. Two similar TCF/LEF motifs are also found in the
human and mouse Cx43 promoters partly at similar positions,
and a third one is located in the first intron [35,70].
In fact, several studies have suggested that Cx43 acts as a
functional target of Wnt1 signaling. van der Heyden et al. [65]
investigated the effects of Wnt1 overexpression on gap-
junctional communication in the rat neural-crest-derived cell
line PC12. They found that Wnt1-expressing clones display an
increased electrical and chemical coupling, which coincides
with an increased expression of Cx43 mRNA and protein,
whereas other connexins, Cx26, Cx32, Cx37, Cx40, and Cx45,
are not upregulated. They also showed in transient transactiva-
tion assays in P19 EC cells that Wnt1 and Li+, an ion that
mimics Wnt signaling, increased transcription from the rat
Cx43 promoter containing exon I and 1250 bp of upstream
sequence, potentially via TCF/LEF binding elements. Ai et al.
[71] also reported that neonatal rat cardiomyocytes responded
to Li+ by accumulating the effector protein h-catenin and by
inducing Cx43 mRNA and protein markedly, and that by
transfecting a Cx43 promoter P1-reporter gene construct into
cardiomyocytes, the inductive effect of Wnt signaling was
transcriptionally mediated.
3.1.6. Ras-Raf-MAPK pathway
Carystinos et al. [37] found that both Cx43 mRNA and
protein levels are increased in H-Ras-overexpressing NIH3T3
cells and that the cells also have enhanced Cx43 promoter P2
activation, which is inhibited by the MEK1 inhibitor. Further-
more, they showed that a 200-bp region downstream of the
Cx43 transcription start site is the minimal sequence essential
for the Ras-mediated Cx43 upregulation and that a protein
complex in nuclear extracts from NIH3T3-Ras and MCF7-Ras
selectively recognizes a consensus sequence, AGTTCAATCA,
located at positions +149 to +158 of the Cx43 promoter P2, in
which complex the 90-kDa heat shock protein (HSP90) and c-
Myc are identified as constituents.
3.2. Cell type-dependent transcription factors and biological
substances that regulate connexin expression
In addition to the maintenance of basal level of connexin
transcription by the cell type-independent (ubiquitous) tran-
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tissue-specific expression of different connexin genes depends
on additional cell type-specific activators or repressors.
Although the molecular mechanisms that regulate cell type-
specific transcription of each connexin gene are still poorly
understood, recent studies have led to a better understanding of
the roles of some cell-type-dependent transcription factors in
regulation of connexin expression. For example, the crucial
roles of cardiac-specific transcription factors in cardiac con-
nexin (Cx40, Cx43, Cx45) expression in the heart have been
confirmed by generation of mutant mice such as mice
expressing wild-type and a mutant Nkx2-5, Nkx2-5 homozy-
gous or heterozygous knockout mice, and Tbx5 homozygous
or heterozygous knockout mice.
3.2.1. Nkx2-5
Nkx2-5 is a homeodomain-containing transcription factor
critical for cardiac development in species ranging from
Drosophila to humans [72,73]. Heterozygous mutations of
Nkx2-5 in humans cause congenital heart disease [74].
Mutations that affect DNA binding are associated with cardiac
conduction defects or heart block. Nkx2-5 mRNA and protein
are transiently upregulated during the formation of cardiac
conduction system relative to the surrounding myocardium in
embryonic chick, mouse, and human hearts, suggesting a role
in the development of the conduction system [75].
Potential Nkx2.5-binding sites have been identified in the
proximal promoters P1 of mouse/rat Cx40 and rat Cx43 genes.
In fact, Linhares et al. [52] demonstrated that Nkx2-5 could
interact specifically with the potential binding site present in
the minimal promoter region of the mouse Cx40.
From the multiple experimental results obtained for mice
expressing wild-type and a mutant Nkx2-5 and for Nkx2-5
homozygous or heterozygous knockout mice, we may con-
clude that Nkx2-5 can act as an activator as well as repressor of
Cx43. Kasahara et al. [76] reported that expression of Cx40
and Cx43 was dramatically decreased in the transgenic heart
expressing a DNA binding-impaired mutant of mouse Nkx2-5,
suggesting a positive role of Nkx2-5 in Cx40 and Cx43 gene
regulation. A subsequent study by Kasahara et al. [77]
demonstrated that cardiomyocytes expressing wild-type
Nkx2.5 or a putative transcriptionally active mutant (carbo-
xyl-terminus deletion mutant) had dramatically reduced ex-
pression of Cx43, and that Cx43 was downregulated in wild-
type Nkx2.5 adenovirus-infected adult cardiomyocytes as early
as 16 h after infection, indicating that Cx43 downregulation is
due to Nkx2.5 overexpression but not due to heart failure
phenotype in vivo. Teunissen et al. [57] also reported that Cx43
protein and mRNA in rat primary neonatal ventricular
cardiomyocytes were significantly decreased after infection
with adenovirus encoding Nkx2.5, and that the rat Cx43
proximal promoter P1 was downregulated approximately 2-
fold upon Nkx2.5 overexpression. These results showed that
Nkx2-5 can act as an activator as well as repressor of Cx43.
Jay et al. [78] found that an entire population of Cx40 ()/
Cx45 (+) cells is missing in the atrioventricular node of Nkx2–
5 heterozygous knockout mice but that, surprisingly, thecellular expression of Cx40, the major gap junction isoform
of Purkinje fibers and a putative Nkx2–5 target, is unaffected.
These data demonstrate that half-normal gene dosage of
Nkx2–5 is sufficient for specific expression of Cx40 in the
conduction system.
Dupays et al. [79] recently investigated cardiac connexin
expression in the cardiovascular systems of wild-type and
Nkx2–5-knockout 9.2 days post-conception (dpc) mouse
embryos and found that the disruption of the Nkx2–5 gene
in the mouse heart results in the loss of Cx43 (due in part to the
poor development of the ventricular trabecular network) and
downregulation of Cx45 gene expression. These results
indicate that Nkx2–5 is involved in the transcriptional
regulation of the Cx45 gene expression. Concerning Nkx2–5
haploinsufficiency, they showed that RNA extracts from wild-
type and heterozygous mutant embryos expressed the Cx45,
43, and 40 genes, and that there were no marked
differences between wild-type and heterozygous mutant
embryos, suggesting that half-normal gene dosage of Nkx2–
5 is sufficient for expression of Cx45, Cx43, and Cx40 in the
hearts of 9.2 dpc mouse embryos.
3.2.2. T-box transcription factors (Tbx5, Tbx2, Tbx3)
T-box transcription factors containing the T-box, which
possesses a helix– loop–helix-type DNA-binding domain,
form a large family that play a crucial role in several
developmental processes [80–82]. This family constitutes
activators (e.g., Tbx5) and repressors (e.g., Tbx2 and Tbx3)
of transcription that recognize the same binding element.
Tbx5 is one member of a transcription factor family
containing the T-box. Tbx5 has been implicated in vertebrate
tissue patterning and differentiation [80]. A role for Tbx5 in
cardiac morphogenesis has been implied from studies of Holt–
Oram syndrome, a rare autosomal dominant human disease
caused by Tbx5 mutations [83–85]. Holt–Oram syndrome
patients invariably exhibit upper limb malformations and have
high incidences of both congenital heart disease, such as
tetralogy of Fallot or hypoplastic left heart syndrome [86–88],
and abnormal cardiac electrophysiology (particularly atrioven-
tricular block). Tbx5 has a unique pattern of expression;
transcripts are abundant in the posterior regions of the
embryonic heart and predominate in the myocardium of the
left atria, right atria, left ventricle, inflow tract (IFT),
atrioventricular canal (AVC), inner curvature, and the atrial
septum. Tbx5 is also expressed in the central conduction
system (CCS), comprising the SA node, atrioventricular
junction including the AV node, and the interventricular (IV)
ring including its derivatives, the retroaortic root branch, right
atrioventricular ring bundle, atrioventricular bundle (AVB), and
proximal part of the BBs. However, expression of Tbx5 is
virtually absent from the right ventricle and outflow tract
(OFT) [88–90].
Potential T-box binding sites have been identified in rat and
mouse Cx40 promoters. Bruneau et al. [91] found five potential
T-box binding sites in 1-kb fragments of mouse and rat Cx40
promoters and showed that Tbx5 binds to at least two of those
sites. Linhares et al. [52] also demonstrated binding of Tbx5 to
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promoter (150 bp upstream of the transcription start site).
A crucial role of Tbx5 in regulation of Cx40 expression has
been revealed by Tbx5 heterozygous knockout (haploinsuffi-
cient) mice, a model of human Holt–Oram syndrome. Bruneau
et al. [91] found that Tbx5 haploinsufficiency markedly
decreased Cx40 mRNA transcription in the heart, indicating
that Cx40 is a Tbx5 target gene and that half-normal gene
dosage of Tbx5 is insufficient for expression of Cx40. They
also showed that when the mouse Cx40 promoter contained
within a 1010-bp fragment joined with reporter luciferase
construct was cotransfected with RSV-promoted Tbx5 cDNA
into noncardiac cells (CV-1), Cx40 promoter activity increased
more than 20-fold, demonstrating that the Cx40 promoter is a
direct Tbx5 target. Furthermore, they observed synergistic
activation of the mouse Cx40 promoter by Tbx5 and Nkx2–5.
In contrast to Nkx2–5, overexpression of Tbx5 has not been
reported to downregulate connexin expression. Using clones of
the P19Cl6 embryonal carcinoma cell line stably transfected
with Tbx5, Fijnvandraat et al. [92] found a strong positive
correlation between the levels of Tbx5 transgene mRNA and of
Cx40 mRNA, indicating that Tbx5 does not function as a
repressor of connexin expression.
Among the T-box transcription factors, Tbx2 and Tbx3
function as repressors of transcription, including that of Cx40
and Cx43 expression. Christoffels et al. [93] showed that when
the putative regulatory sequences of mouse Cx40 (a 1.2-kb
mouse Cx40 upstream region from 1196 to +62 relative to
the transcription start site) and rat Cx43 (a 1.6-kb rat Cx43
upstream region from 1338 to +281) were coupled to the
luciferase reporter gene and transfected to Cos-7 or HEK cells,
Cx40 promoter activity and to a lesser extent Cx43 promoter
activity were repressed by Tbx2. They also found that at mouse
developmental stages (embryonic days 9.5–14.5), expression
patterns of Tbx2 and cardiac chamber-specific genes including
Cx40 and Cx43 were mutually exclusive in the myocardium.
Tbx2 is expressed in the IFT, AVC, inner curvature, and OFT,
whereas no Tbx2 expression could be observed in the atrial and
ventricular chamber myocardium. On the other hand, Cx40 and
Cx43 are expressed in the atrial and ventricular chamber
myocardium, but absent in the IFT, AVC, inner curvature, and
OFT. These data indicate a role of Tbx2 in the repression of the
connexin genes in hearts in vivo.
Hoogaars et al. [90] showed that, similarly to Tbx2, the
patterns of Tbx3 and cardiac chamber-specific genes including
Cx40 and Cx43 are mutually exclusive throughout all stages of
mouse heart development (E9–E17.5). In the formed heart,
Tbx3 is expressed in the central conduction system, comprising
the SA node, AV node, bundle and proximal BBs, as well as
the internodal regions and the atrioventricular region. Expres-
sion of Cx40 and Cx43 is specifically absent from the Tbx3
expression domain. However, there are some exceptions: at
E15.5, weak Tbx3 expression protrudes further into the
proximal BB which by then also expresses Cx40, and at
E17.5, when the heart has reached its mature form, the AVB
expresses low levels of Cx40, coexpressed with Tbx3.
Hoogaars et al. [90] also demonstrated that Tbx3 dose-dependently represses the activity of mouse Cx40 promoter
contained in 1.2-kbp Cx40 upstream regulatory region 1196
to +62 relative to the transcription start site. Interestingly, in the
adult myocardium, Cx45 is expressed in all components of the
conduction system including the Tbx3-positive central con-
duction system and the Tbx3-negative peripheral conduction
system encompassing the distal part of the BBs plus the
peripheral ventricular conduction network (the Purkinje fibers).
To summarize, the cardiac expression of Tbx2 decreases
from the early stage of heart development, whereas that of
Tbx3 increases. Given that Tbx2 and Tbx3 share structure,
repressor function, and DNA recognition domain, combined
repressive function of Tbx2 and Tbx3 seems to play crucial
roles in regional specific expression of Cx40 and Cx43. On the
other hand, expression of Cx45 in the heart seems to be
regulated independently of repressive function of Tbx2 and
Tbx3.
Apart from regulation of connexin expression in the heart,
Chen et al. [94] reported that in osteoblast-like cells, the mouse
Cx43 promoter (479 to 0) contains two Tbx2 binding sites.
This binding was dependent on the TCACAC consensus
sequence, and transient transfection analysis with a Cx43
promoter-driven lacZ reporter construct revealed negative
regulation of Cx43 transcription mediated by these two Tbx2
binding sites.
3.2.3. GATA family
GATA transcription factors contain a highly conserved DNA
binding domain consisting of two zinc fingers of the motif
Cys–X2–Cys–X17–Cys–X2–Cys that directs binding to the
nucleotide sequence element (A/T)GATA(A/G) [95]. Based on
their expression patterns, the GATA proteins have been divided
into two subfamilies, GATA-1, -2, and -3 and GATA-4, -5, and
-6. GATA-1, -2, and -3 genes are prominently expressed in
hematopoietic stem cells, where they regulate differentiation-
specific gene expression in T-lymphocytes, erythroid cells, and
megakaryocytes. GATA-4, -5, and -6 genes are expressed in
various mesoderm- and endoderm-derived tissues such as
heart, liver, lung, gonad, and gut, where they play critical
roles in regulating tissue-specific gene expression.
Linhares et al. [52] showed that GATA4 can interact
specifically with its putative site (49, 36) in the rat/mouse
Cx40 proximal promoter, and that the coexpression of GATA4
induced an approximate 6-fold increase in luciferase activity
from 1190/+ 121Cx40Luc. Addition of Nkx2–5 with
GATA4 led to a 10-fold increase in activation. The same effect
was observed when the minimal promoter 50/+ 121 Cx40Luc
construct was used, indicating that this region contains the sites
required for activation of Cx40 expression by both Nkx2–5
and GATA4 transcription factors.
3.2.4. HNF-1
HNF-1 is a transcription factor whose expression has been
positively correlated with the differentiated hepatic phenotype
and positively regulates many liver-specific genes, e.g., a1-
antitrypsin, albumin, and a- and h-fibrinogen [96]. Two
isoforms, HNF-1a and HNF-1h, are known; the former is
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earlier in development. HNF-1 isomers dimerize in a homo-
meric or heteromeric manner before binding to DNA, and each
combination can have distinct effects on transcriptional control,
depending upon the target gene. HNF-1 is also expressed in
other tissues such as kidney, gut, and pancreas, where it
controls the expression of many genes.
Hennemann et al. [25] first reported that the promoter region
of the mouse Cx32 gene contains two putative binding sites for
HNF-1 within 680 bp upstream of the main transcription start
site. Piechocki et al. [22] showed that promoter activity of the
rat Cx32 promoter (nt 753 to 33) linked to the luciferase
gene was correlated with the binding of HNF-1 to two HNF-1
consensus sites centered at 187 and 736, and that
expression of HNF-1 and binding to these elements was only
observed with rat hepatoma (MH1C1) cells that express
endogenous Cx32. Koffler et al. [26] demonstrated that stable
transfection of non-Cx32-expressing WB-F344 rat liver epi-
thelial cells with HNF-1a stimulated a transfected Cx32
promoter element (mp 244 to 33), binding of HNF-1a to
the 187 site, and expression of endogenous Cx32, and that
Cx32 expression was also significantly decreased in HNF-1a
(/) mice. These data suggest that HNF-1 determines the
cell-specific expression of Cx32 based on the cell-type-
independent activation of Cx32 promoter by ubiquitous
transcription factors such as Sp1 as described above.
3.2.5. Mist1
Mist1 is one of the members of the basic helix–loop–helix
(bHLH) protein family that are instrumental in development of
numerous organ systems. Rukstalis et al. [97] found that Mist1
knockout (KO) pancreatic acini are deficient in gap-junctional
intercellular communication, mainly due to the loss of Cx32
expression, and that Cx32 mRNA and protein levels are greatly
reduced in the Mist1 KO exocrine pancreas, whereas Mist1 KO
acinar cells continue to express the Cx26 gene. They also
showed that co-transfection of cells with the mouse Cx32 P1
promoter (680 to +20)-luciferase reporter plasmid (Cx32p-
Luc) and an expression plasmid encoding Mist1 generated a
15- to 20-fold increase in Cx32p-Luc expression, whereas no
other bHLH transcription factor such as E12, E47, HEB, PTF1-
p48, NeuroD, MyoD, and Mash1, could activate expression of
the Cx32p-Luc gene. The ability of Mist1 to activate
expression of the Cx32p-Luc gene was dependent on its
DNA binding and dimerization properties. From those results,
it is concluded that an active Mist1 protein is required to
generate full Cx32 gene expression in secretory acinar cells.
Concerning tissue-specific Cx32 expression, combined data
on Mist1 [97] and HNF-1 indicate that there are at least two
different activation mechanisms of Cx32 expression in the
epithelial cell: Mist1-dependent expression in secretory exo-
crine cells, including the pancreas, submandibular gland,
parotid gland and seminal vesicles and HNF-1-dependent
expression in the hepatocyte. Rukstalis et al. [97] described
that Cx32 and Mist1 co-expression is observed in all secretory
exocrine cells, including the pancreas, submandibular gland,
parotid gland and seminal vesicles, whereas hepatocytesexpress Cx32 but not Mist1. Furthermore, they showed that
in the liver tissue of Mist1 KO mice, expression of Cx32
transcripts and formation of Cx32-containing gap junction
plaques remained unchanged, indicating that Cx32 expression
in the liver is independent of Mist1. On the other hand, Koffler
et al. [26] reported that Cx32 mRNA content in HNF-1a
homozygous KO mouse liver was approximately one third that
of HNF-1a heterozygous KO mice, suggesting a crucial effect
of HNF-1 on Cx32 in the hepatocyte.
3.2.6. Sox10 and early growth response gene-2 (Egr2/Knox20)
The Sox proteins belong to the high mobility group (HMG)
box superfamily of DNA-binding proteins. Among them,
Sox10 is first expressed widely in cells of the neural crest at
the time of their emergence, and later in neural crest cells that
contribute to the melanocyte lineage and to the forming
peripheral nervous system. Its expression is detected in the
enteric, sensory, and sympathetic ganglia as well as along
nerves in a manner typical for the Schwann cell lineage [98].
The early growth response gene-2 (Egr2/Knox20) gene was
originally identified as a serum response immediate-early gene
that encodes a protein with three tandem zinc fingers of
cys(2)–his(2) class [99–101]. Egr2/Krox20 knockout mice
showed disrupted hindbrain segmentation and development
and a block of Schwann cells at an early stage of differentiation
[102,103].
Mutations in Sox10 genes are discovered in patients with
various hereditary neurological diseases including Waarden-
burg–Hirschsprung disease or Shah–Waardenburg syndrome
(WS4), and WS4 with peripheral neuropathy consistent with
Charcot–Marie–Tooth disease type I [98]. Mutations in Egr2/
Krox20 gene are identified in patients with congenital
hypomyelinating neuropathy and a family with Charcot–
Marie–Tooth disease type 1D (CMT1) [103].
Bondurand et al. [27] showed that Sox10, in synergy with
Egr2/Knox20, strongly activates expression of Cx32, a major
protein of peripheral myelin, in vitro by directly binding to its
nerve-specific promoter P2, and that Sox10 and Egr2 mutants
identified in patients with peripheral myelin defects failed to
transactivate the Cx32 promoter P2. They also demonstrated
that a T-to-G point mutation at position 528 of the Cx32
promoter P2 identified in some CMTX1 patients eliminates
binding and activation by Sox10. Similarly, Houlden et al. [28]
identified a large family with Charcot–Marie–Tooth disease
with a G-to-C point mutation at position 526 bp of the Cx32
promoter P2 and showed that this mutation reduced the activity
of the Cx32 promoter and the affinity for Sox10 binding. These
data suggest that interaction between the Cx32 P2 promoter,
Sox10, and Egr2 plays an important role in Cx32 expression in
the Schwann cell.
In addition to Cx32, Jungbluth et al. [104] reported that
segment-specific expression of Cx31 in the mouse embryonic
hindbrain is positively regulated by Egr-2/Krox20. They found
that the spatiotemporal patterns of Cx31 expression in
rhombomeres 3 and 5 and in the boundary cap cells are very
similar to the expression pattern of Egr2/Krox20, and that in
Egr2/Krox20 KO embryos, no Cx31 expression was detectable
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other sites nonoverlapping with that of Egr2/Krox20, such as in
the posterior end of the embryonic body axis, were not affected
in Egr2/Krox20 KO embryos.
3.2.7. Estrogen
Cx43 expressed in the uterus is thought to play a critical
role in the onset of labor by allowing for an increase in
myometrial cell coupling and coordinated synchronous con-
traction of the muscle at the end of pregnancy. Before the
onset of labor, there is a dramatic increase in both mRNA and
protein levels of Cx43 in the myometrium [105,106]. The
Cx43 gene in the myometrium is under the control of steroid
hormones, being upregulated by estrogen and downregulated
by progesterone [107]. Yu et al. [34] showed that the rat Cx43
promoter contains several sequences resembling half the
palidromic estrogen response elements (half-EREs); depending
on the concentration of estrogen, the half-EREs were
functional when cotransfected with estrogen receptor cDNA
into HeLa cells.
However, Oltra et al. [108] described that these half-EREs
are not required for the induction of the Cx43 gene; a promoter
containing only 145 nucleotides and lacking all half-EREs was
shown to be sufficient to achieve full estrogen response. It has
also been reported that elevated Cx43 expression in term
human myometrium is independent of myometrial estrogen
receptors [59]. On the other hand, it has been shown that the
expression of several AP-1 family transcription factors (c-jun
and c-fos family of transcription activators) is dramatically
increased in the myometrium before the onset of labor and that
this expression is regulated by both mechanical and hormonal
stimuli [35,59,62]. Therefore, AP-1 proteins play crucial roles
in positive regulation of Cx43 expression in the pregnant
myometrium as described above.
Besides AP-1 proteins, Oltra et al. [108] reported that Ini, a
small nuclear zinc-finger protein, actively participates in the
positive response of Cx43 expression to estrogen. They
showed that Ini binds to the rat proximal Cx43 promoter
between 71 and 34, its expression is ubiquitous, and in the
uterus is upregulated by estrogen. Furthermore, transient
transfection experiments performed with estrogen receptor
alpha cDNA show that overexpression of Ini enhances, in a
dose-dependent fashion, the upregulation of the Cx43 gene by
estrogen.
3.2.8. Thyroid hormone and parathyroid hormone
Stock and Sies [109] demonstrated that after treatment with
thyroid hormone Cx43 mRNAwas elevated 2.1-fold in rat liver
samples as compared to controls, while there was no change in
the heart. They identified thyroid hormone response elements
in the rat Cx43 promoter region at positions 480 to 464 and
showed that the Cx-480 element formed stronger complexes
with thyroid hormone receptor alpha/retinoid X receptor alpha
heterodimers than with vitamin D receptor/retinoid X receptor
alpha heterodimers. In transfected Cos-7 cells, promoter
activation via this element was observed after treatment with
3,3V,5-triiodo-l-thyronine.Mitchell et al. [110] showed that in the rat osteosarcoma
cell line, parathyroid hormone (PTH) induced a 4-fold
increase in activity of Cx43 promoter containing 1.6 kb 5V
of the transcription start site, in which responsive sequence
was localized to between 31 and +1 bp. They demon-
strated that PTH treatment of transgenic mice containing the
1.6 kb promoter luciferase construct induced increases in
luciferase and Cx43 immunoreactivity in bone cells under-
lying the tibial growth plate. They also found that the full
Cx43 3VUTR conferred a 3-fold response to PTH when
placed 3V of a CMV-luciferase construct, in which respon-
sive sequence was localized to between 2510 and 3132 of
the 3V-UTR. These data indicate that PTH responsive
sequences are present in the Cx43 promoter and 3V-UTR,
suggesting that transcriptional and posttranscriptional path-
ways operate to regulate PTH-induced Cx43 expression in
osteoblast cells.
3.2.9. Other transcription regulators of connexin expression
Martin et al. [111] reported that the transcriptional repressor
neuron-restrictive silencer factor (NRSF) controls neuron- and
beta-cell-specific expression of Cx36 expression. They identi-
fied a putative neuron-restrictive silencer element conserved
between rodent and human species in a 2043-bp fragment of
the human Cx36 promoter, and showed that NRSF binds the
neuron-restrictive silencer element. They also demonstrated
that this factor is not expressed in insulin-secreting cells and
neurons; viral gene transfer of NRSF in insulin-secreting beta-
cell lines induced a marked reduction in Cx36 mRNA;
repression of Cx36 expression by NRSF is mediated through
the recruitment of histone deacetylase to the promoter of
neuronal genes.
Ciliary neurotrophic factor (CNTF) is a member of the IL-
6 family that is produced as a nonsecreted cytosolic cytokine
by astrocytes within the central nervous system and has its
specific receptor, termed ciliary neurotrophic factor receptor
alpha (CNTFRalpha), located on neuronal cell membranes.
Ozog et al. [112] demonstrated that the heterodimer CNTF-
CNTFRalpha significantly increased Cx43 mRNA in normal
astrocytes in a Janus tyrosine kinase/signal transducer and
activator of transcription (JAK/STAT)-dependent manner,
whereas CNTF-CNTFRalpha did not alter Cx30 mRNA
levels. In the promoter P1 region of mouse Cx43, they
identified three putative CNTF-response elements (binding
sites for STAT3 dimers that contain base sequences
TTCCN3–5AA) and showed that these three elements, located
at regions 1510, 1179, and 893, are essential for Cx43-
regulated expression by CNTF-CNTFRalpha.
3.3. Gene silencing by DNA methylation of the connexin
promoters
The downregulation of connexin expression is often
observed in tumors and transformed cell lines and is believed
to contribute to the loss of proliferating control. Despite
intensive studies, neither deletion nor mutation of connexin
gene has been found in human tumors.
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inactivation through hypermethylation of the promoter region
could lead to silencing of connexin expression. Piechocki et
al. [113] analyzed methylation states of Cx32 and Cx43
promoters using MH1C1 rat hepatoma cells that express Cx32
but not Cx43 and WB-F344 rat liver epithelial cells that
express Cx43 but not Cx32. They found that two MspI/HpaII
restriction sites in the Cx32 promoter (positions 147 and
847) were methylated in WB-F344 cells, but not in MH1C1
cells, whereas an MspI/HpaII restriction site in the Cx43
promoter (position 38) was methylated in MH1C1 cells but
not in WB-F344 cells. These results suggest that transcription
of Cx32 and Cx43 in hepatic cells is controlled by promoter
methylation and by cell-specific transcription factors. Tan et
al. [114] performed methylation-sensitive single-stranded
conformation analysis and found Cx26 promoter methylation
in 11 out of 20 human breast cancer tissues and one of eight
breast cancer cell lines. They also showed that the most
frequently methylated CpG was position 81 in an Sp1 site
known to be important for Cx26 gene expression and that
treatment of a breast cancer cell line (MD-MBA-453) that was
methylated in the Cx26 promoter and did not express Cx26
with 5-aza-2V-deoxycytidine resulted in the re-expression of
Cx26 mRNA. Chen et al. [115] reported that in human non-
small cell lung cancers, lack of Cx43 mRNA expression in
adjacent normal lung tissue was significantly correlated with
micrometastasis into lymph nodes and that a higher frequency
of promoter methylation was observed in Cx43 mRNA-
negative patients compared with Cx43 mRNA-positive
patients. Their data also indicate that promoter methylation
may interfere with AP1 binding to the promoter, resulting in
lack of Cx43 gene expression. Hirai et al. [116] showed that
Cx32 expression is downregulated in a human renal cell
carcinoma cell (Caki-2 cell) and that hypermethylation in the
promoter region is a mechanism for the Cx32 gene repression.
Yano et al. [117] also found that the inactivation of Cx32
through hypermethylation of the promoter regions frequently
occurred in non-cancerous regions as well as cancerous
regions of kidneys from hemodialysis patients, whereas the
hypermethylation of Cx32 occurred only in cancerous regions
and not in non-cancerous regions of kidneys from the general
patients without hemodialysis.
In contrast to the role of hypermethylation of promoters in
downregulation of connexin expression in the cancer cell,
Singal et al. [118] found no clear correlation between Cx26
expression and hypermethylation of Cx26 5V regions in an
immortalized human mammary epithelial cell line (MCF-10)
and breast cancer cell lines (MDA-MB231, MCF-7, BT-20,
T47-D) and showed that treatment with 5-Aza-CdR resulted in
slight or no induction in Cx26 expression in breast cancer cell
lines, concluding that hypermethylation is unlikely to be a
major mechanism for Cx26 gene repression in human
mammary cancer cell lines. Similarly, using several TE cell
lines derived from different human esophageal carcinomas and
exhibiting different levels of Cx26 expression, Loncarek et al.
[119] found no correlation between the Cx26 expression and
the methylation level of the promoter region of the Cx26 gene,suggesting that methylation was probably not involved as a
primary mechanism of Cx26 regulation in human esophageal
cancer cell lines.
4. Post-transcriptional regulation of connexin expression
Although regulation at the transcriptional level is expected
to be a major determinant in connexin gene expression, other
mechanisms clearly may influence the level of expression as
well.
4.1. Translational control of connexin expression by internal
ribosome entry site (IRES)
Recently, there have been examples of internal ribosome
entry site (IRES)-containing cellular mRNAs that are trans-
lated in cells under normal physiological conditions in which
cap-dependent translation is suppressed, specifically, during
mitosis, cell stress and apoptosis, cap-dependent translation is
shut down, but translation of some proteins important for
these biological processes continues. Because IRESs have
been identified in some connexin genes, such as Cx43, Cx32,
and Cx26, connexin expression could also be regulated by
cap-independent translation. Schiavi et al. [120] found that
when 5V-UTR of rat Cx43 was inserted between the two
genes of a bicistronic vector and transfected into various cell
lines, expression of the second gene was significantly
increased, demonstrating that the Cx43 5V-UTR contains a
strong IRES. Hudder and Werner [121] discovered an IRES
element in the 5V-UTR of the nerve-specific Cx32 mRNA, in
which a mutation (a C to T transition at position 458 in
relation to the start codon) was found in a family with X-
linked Charcot–Marie–Tooth disease (CMTX). Because the
mutation did not facilitate translation of the second gene in
the bicistronic mRNA system, they suggested that this CMTX
mutation abolished function of IRES in the 5V-UTR of the
wild-type connexin-32 mRNA, leading to a CMTX pheno-
type, motor and sensory neuropathy. Lahlou et al. [122] found
that the restoration of density inhibition of human pancreatic
cancer cells by the antiproliferative somatostatin receptor 2 is
due to overexpression of endogenous connexins Cx26 and
Cx43 and consequent formation of functional gap junctions,
and that connexin expression is enhanced at the level of
translation but is not sensitive to the inhibition of cap-
dependent translation initiation. Furthermore, they identified a
new IRES in the Cx26 mRNA and showed that the activities
of Cx26 IRES and Cx43 IRES are enhanced in density-
inhibited cells, suggesting that the existence of IRESs in
connexin mRNAs permits connexin expression in density-
inhibited or differentiated cells, where cap-dependent transla-
tion is generally reduced.
However, it should be noted that criteria which had been
used in identifying putative IRES elements in cellular
mRNAs for Cx43 [120] and Cx32 [121] were criticized in
a review by Kozak [123], who argued that the absence of
RNA analyses does not justify classifying these sequences as
IRESs.
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open reading frames (uORFs)
Another type of translational control in eukaryotes is
effected by one or more short upstream open reading frames
(uORFs) that lie between the 5V end of the mRNA and the
beginning of the main ORF. An uORF present on an mRNA
molecule generally decreases translation of the downstream
gene by trapping a scanning ribosome initiation complex.
Meijer et al. [124] found that the Xenopus laevis Cx41 mRNA
contains three uORFs in the 5V-UTR and analyzed the
translation efficiency of constructs containing the Cx41 5V-
UTR linked to the green fluorescent protein reporter after
injection of transcripts into Xenopus embryos. They showed
that although the translational efficiency of the wild-type Cx41
5V-UTR was only 2% compared with that of the beta-globin 5V-
UTR, mutation of each of the three upstream AUGs (uAUGs)
into AAG codons enhanced translation 82-, 9-, and 4-fold
compared with the wild-type Cx41 5V-UTR. They concluded
that the three uORFs may play an important role in the
regulation of Cx41 expression. Pfeifer et al. [36] found that
among various mouse Cx43 transcripts, the Cx43 5V-UTRs
with higher translation efficiencies lack uAUG, whereas those
with lowest translational activities contain uAUGs with
adequate Kozak consensus sequences. Anderson et al. [30]
reported that a subset of the transcripts for mouse Cx31, Cx45,
Cx46, and Cx47 contain uORFs.
5. Perspectives
As detailed above, recent works demonstrate that the usage
of alternative promoters to produce different 5V untranslated
regions of connexin mRNAs is not unique to only a few of
the connexin genes but is likely a more common feature. It
has also been shown that nearly all of the mRNA variants for
each connexin gene are expressed in a tissue-specific manner.
In more complex processes, such as developmental and
pathological states in vivo, connexin expression could be
controlled by multiple different regulatory modules, which
consist of multiple promoters, variable 5V-UTRs, and IRES
elements in the connexin genes. However, the information on
transcription factors that regulate connexin expression pre-
sented in this article is confined to that concerning the
canonical proximal promoters of connexin genes with some
exceptions. Mapping and functional characterization of
consensus transcription factor binding sites in the alternative
promoters and noncoding exons of connexin genes will surely
help us to further understand regulation of connexin gene
expression.
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